Evidence map›Paper›PMID 25249007›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2015

Transducin-like enhancer of split 3 (TLE3) in adipose tissue is increased in situations characterized by decreased PPARγ gene expression.

Francisco José Ortega, Marta Serrano, Sergio Rodriguez-Cuenca, José María Moreno-Navarrete, María Gómez-Serrano, Mònica Sabater, Jose Ignacio Rodriguez-Hermosa, Gemma Xifra, Wifredo Ricart, Belén Peral and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. TLE3 represses colorectal cancer proliferation by inhibiting MAPK and AKT signaling pathways.Journal of experimental & clinical cancer research : CR · 2016
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Francisco José OrtegaDepartment of Diabetes, Endocrinology and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBERobn (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), Carretera de França s/n, 17007, Girona, Spain, faloides@hotmail.com.
Marta Serrano
Sergio Rodriguez-Cuenca
José María Moreno-Navarrete
María Gómez-Serrano
Mònica Sabater
Jose Ignacio Rodriguez-Hermosa
Gemma Xifra
Wifredo Ricart
Belén Peral
Antonio Vidal-Puig
José Manuel Fernández-Real
Institut d'Investigació Biomèdica de Girona · ESCentro de Investigación Biomédica en Red · ESConsejo Superior de Investigaciones Científicas · ESInstituto de Salud Carlos III · ESNational Institute for Health Research · GBUniversity of Cambridge · GB

Funding

Medical Research Council G0600717Medical Research Council G0802051Medical Research Council MC_UU_12012/2Medical Research Council MC_UU_12012/5
6 · The paper itself

Abstract

unlabelledTransgenic overexpression of adipose tissue (AT) transducin-like enhancer of split 3 (TLE3) mimicked peroxisome proliferator-activated receptor gamma (PPARγ) agonists, improving insulin resistance in mice. This study aimed to investigate TLE3 gene expression (qRT-PCR) and protein (Western blot) in subjects with a wide spectrum of obesity and insulin sensitivity and in an independent cohort of obese subjects following surgery-induced weight loss. TLE3 was analyzed in human adipocytes and after treatment with rosiglitazone. Given the findings in humans, TLE3 was also investigated in mice after a high-fat diet (HFD) and in PPARγ knockout mice. Subcutaneous (SC) AT TLE3 was increased in subjects with type 2 diabetes (T2D). In fact, SC TLE3 was associated with increased fasting glucose (r = 0.25, p = 0.015) and S6K1 activity (r = 0.671, p = 0.003), and with decreased Glut4 (r = -0.426, p = 0.006) and IRS-1 expression (-31 %, p = 0.007) and activation (P-IRS-1/IRS-1, -17 %, p = 0.024). TLE3 was preferentially expressed in mature adipocytes and increased during in vitro differentiation in parallel to PPARγ. Weight loss led to improved insulin sensitivity, increased AT PPARγ and decreased TLE3 (-24 %, p = 0.0002), while rosiglitazone administration downregulated TLE3 gene expression in fully differentiated adipocytes (-45 %, p < 0.0001). The concept that TLE3 may act as a homeostatic linchpin in AT was also supported by its increased expression in HFD-fed mice (39 %, p = 0.013) and PPARγ knockout (74 %, p = 0.001). In summary, increased AT TLE3 in subjects with T2D and in AT from HFD-fed and PPARγ knockout mice suggest that TLE3 may play an adaptive regulatory role that improves AT function under decreased PPARγ expression. KEY MESSAGE: TLE3 is expressed in mature adipocytes concomitantly with PPARγ. Subcutaneous adipose TLE3 is increased in T2D patients. Adipose TLE3 is upregulated in genetically ablated PPARγ and HFD-fed mice. TLE3 may be a homeostatic linchpin in insulin resistance and defective PPARγ.

Indexed as

AdipocytesAdipose TissueAdultAnimalsCo-Repressor ProteinsDiabetes Mellitus, Type 2Diet, High-FatFemaleGene ExpressionHumansInsulin ResistanceMaleMice, Inbred C57BLMice, KnockoutMiddle AgedObesity, MorbidCo-Repressor ProteinsPPAR gammaRNA, MessengerTLE3 protein, human

Identifiers

PMID25249007
OpenAlexW1974608549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.